News | Nuclear Imaging | July 27, 2022

House-passed Appropriations Bills Include Key Measures to Improve Nuclear Medicine Patient Safety 

House-passed Appropriations Bills Include Key Measures to Improve Nuclear Medicine Patient Safety

July 27, 2022 — Patients for Safer Nuclear Medicine, a coalition of 29 patient advocacy organizations representing thousands of patients, along with more than 600 concerned US citizens today praised the House of Representatives for passing two appropriations bills that include important language calling on federal agencies to improve patient safety in nuclear medicine

Radioactive drug misadministrations caused by human error, inadequate training, lack of quality procedures, and that exceed defined radiation dose thresholds are currently reportable to NRC. Extravasations occur when radioactive drugs used in nuclear medicine procedures are inadvertently injected into the patient’s tissue instead of a vein.  Despite potential consequence to patient safety, even the most severe extravasations are exempted from NRC reporting requirements due to a 42 year-old loophole in NRC policy. 

Appropriations bills passed by the House of Representatives last week call on the U.S. Nuclear Regulatory Commission (NRC) to update its internal rules on reporting significant unintended irradiation, and call on the Veterans Health Administration to monitor injection quality and report significant extravasations. 

“30 million administrations of radioactive drugs occur every year in the US, but NRC has excluded extravasations from reporting, even if they cause radiation doses hundreds of times higher than other reportable events,” says Patients for Safer Nuclear Medicine spokesperson Mary Ajango. “Patients need to know if their care is affected. The worst approach is to do nothing and wait for patients to be injured.” 

The House-passed package of Appropriations bills included the following language regarding NRC: Re-Evaluation of Nuclear Medicine Event Reporting —The Committee is closely monitoring the Commission’s reconsideration of its policy related to significant extravasations and medical event reporting. Evidence shows that nuclear medicine extravasations may be avoidable and that some extravasations may exceed medical event reporting provided in 10 C.F.R. Part 35 Subpart M. These events may harm patients through unintended radiation exposure, compromised imaging that negatively affects care, additional interventional procedures, and repeated imaging procedures. The Committee continues to encourage the Commission to consider the inclusion of significant extravasations in medical event reporting to improve safety, quality, and transparency for patients, treating physicians, and the Commission itself. 

The package also included the following language regarding the VA: 

Nuclear Medicine Quality Improvements —The Committee is aware of the consequence of extravasations in nuclear medicine procedures, and understands that the Nuclear Regulatory Commission and Centers for Medicare and Medicaid Services are considering regulatory actions to improve nuclear medicine injection quality. The Committee continues to encourage VA to monitor injection quality, as well as image extravasations, perform dosimetry and notify patients when they occur, and urges the Department to adopt any new regulatory requirements. 

For more information: https://www.unchealthcare.org/


Related Content

News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | Radiology Business

July 31, 2024 — The American Registry of Radiologic Technologists (ARRT) announced the three Registered Technologists (R ...

Time July 31, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Prostate Cancer

July 30, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 30, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 25, 2024 — NorthStar Medical Radioisotopes, LLC and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc ...

Time July 25, 2024
arrow
News | PET-CT

July 25, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET & PET-CT imaging ...

Time July 25, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
News | Radiation Therapy

July 22, 2024 — RefleXion Medical, an external-beam theranostic oncology company, today announced that researchers from ...

Time July 22, 2024
arrow
News | ASTRO

July 18, 2024 — The members of the American Society for Radiation Oncology (ASTRO) recently elected five new officers to ...

Time July 18, 2024
arrow
Subscribe Now